Mokari Atabak's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Jun 17, 2026
- Accession no.
- 0001193125-26-274224
- Filed
- Jun 17, 2026
- Trade date
- Jun 15, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.25M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mokari AtabakCIK 0001678419 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Common Stock | MOption exerciseAcquired | +40,000 | $19.26 | +$770,400 | 56,130 | Direct | |
| Jun 15, 2026 | Common Stock | SSaleDisposed | −9,434 | $80.02F3 | −$754,908.68 | 46,696 | Direct | |
| Jun 15, 2026 | Common Stock | SSaleDisposed | −11,081 | $80.94F4 | −$896,896.14 | 35,615 | Direct | |
| Jun 15, 2026 | Common Stock | SSaleDisposed | −19,483 | $81.81F5 | −$1,593,904.23 | 16,132 | Direct | |
| Jun 15, 2026 | Common Stock | SSaleDisposed | −2 | $82.45 | −$164.9 | 16,130 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Common Stock | MOption exerciseDisposed | −40,000 | $0.00 | $0 | 20,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $80.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.40 to $81.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F5
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.40 to $82.18 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
The power of attorney under which this form was signed is on file with the Commission.